The purchase signals mild confidence from a board member, but the dollar amount is too small relative to market cap to suggest strong conviction or serve as a catalyst. Traders should monitor for follow-up buying, especially from C-suite executives.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 27 $13.27entry
- T+1 · 9mo ago +0.90%α +0.85% · $13.39
- T+5 · 9mo ago +2.49%α +4.47% · $13.60
- T+20 · 8mo ago −23.89%α −16.33% · $10.10
- T+60 · 6mo ago −32.78%α −42.17% · $8.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A director at Arvinas, Inc. purchased $268,070 worth of shares in an open-market transaction, marking the only insider activity in the past seven days. This is a modest-sized purchase relative to the company's $870M market cap, representing approximately 0.03% of market value.
Key Financial Metrics
Key Facts
- Director Morrison Briggs purchased 20,000 shares at $13.4035 per share for a total of $268,070.
- Transaction occurred on March 6, 2026, in the open market (Form 4 code 'P').
- Only one insider transaction in the past 7 days; no sales or other activity during this window.
- Total value represents ~0.03% of Arvinas' $870M market capitalization.
Financial Impact
$268,070 in open-market buying by a director
Risk Factors
- Single transaction by a non-executive director carries limited predictive power.
- No additional insider participation or recent pattern of buying to reinforce the signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (1 trades, 7d window) | cluster-ARVN-1773086754033 |
Track record
21 reports on ARVN
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers